collection
MENU ▼
Read by QxMD icon Read
search

Osteoporosis

shared collection
102 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28912972/denosumab-for-male-hemodialysis-patients-with-low-bone-mineral-density-a-case-control-study
#1
Hiroya Takami, Kazunori Washio, Hiromichi Gotoh
Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9...
2017: International Journal of Nephrology
https://www.readbyqxmd.com/read/28892459/romosozumab-promising-or-practice-changing
#2
Clifford J Rosen
No abstract text is available yet for this article.
September 11, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28854619/amgen-and-ucb-announce-increased-cardiovascular-risk-in-patients-receiving-romosozumab-an-anti-sclerotin-antibody
#3
(no author information available yet)
No abstract text is available yet for this article.
August 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28786812/the-role-of-exercises-in-osteoporotic-fracture-prevention-and-current-care-gaps-where-are-we-now-recent-updates
#4
REVIEW
Helen Senderovich, Henry Tang, Samuel Belmont
INTRODUCTION: The primary non-pharmacological management recommended for patients with osteoporosis (OP) is exercise, but whether it should be high-force, resistive, or other means can be obscure. OBJECTIVE: To describe the role of exercises in osteoporotic fracture prevention, identify effects and potential risks of high-force exercises, detect the optimal exercises to combat OP, and explore the challenges that might arise from interventions. METHODS: A search on MEDLINE and Cochrane databases was conducted on the role of exercises in preventing osteoporotic fractures from 1989 onwards, leading to 40 results, including op-ed pieces, qualitative studies, randomized clinical trials (RCTs) (n=5), and RCT follow-up studies (n=1)...
July 1, 2017: Rambam Maimonides Medical Journal
https://www.readbyqxmd.com/read/28713268/sitagliptin-an-anti-diabetic-drug-suppresses-estrogen-deficiency-induced-osteoporosisin-vivo-and-inhibits-rankl-induced-osteoclast-formation-and-bone-resorption-in-vitro
#5
Chuandong Wang, Fei Xiao, Xinhua Qu, Zanjing Zhai, Guoli Hu, Xiaodong Chen, Xiaoling Zhang
Postmenopausal osteoporosis is a disease characterized by excessive osteoclastic bone resorption. Some anti-diabetic drugs were demonstrated for anti-osteoclastic bone-loss effects. The present study investigated the skeletal effects of chronic administration of sitagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor that is increasingly used for type 2 diabetes treatments, in an estrogen deficiency-induced osteoporosis and elucidated the associated mechanisms. This study indicated that sitagliptin effectively prevented ovariectomy-induced bone loss and reduced osteoclast numbers in vivo...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28669103/disease-modifying-anti-rheumatic-drug-effect-of-denosumab-on-radiographic-progression-in-rheumatoid-arthritis-a-systematic-review-of-the-literature
#6
Gonçalo Boleto, Moustapha Dramé, Isabelle Lambrecht, Jean-Paul Eschard, Jean-Hugues Salmon
The aim of this study was to evaluate the structural effect of denosumab on patients with rheumatoid arthritis (RA). We performed a systematic review of the literature in the following databases: PubMed, Cochrane, Web of Science, ClinicalTrials.gov , and the WHO International Clinical Trials Registry Platform. All studies evaluating the structural effect of denosumab on RA and meeting predefined criteria were included. Data regarding disease activity, progression of joint damage, joint space narrowing, and safety were recorded...
August 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28646239/intake-of-omega-3-fatty-acids-contributes-to-bone-mineral-density-at-the-hip-in-a-younger-japanese-female-population
#7
T Kuroda, H Ohta, Y Onoe, N Tsugawa, M Shiraki
This study investigated the relationships between intakes of polyunsaturated fatty acids, omega-3 fatty acids, and omega-6 fatty acids and bone mineral density in Japanese women aged 19 to 25 years. Intakes of omega-3 fatty acids (n-3) were positively associated with peak bone mass at the hip. INTRODUCTION: Lifestyle factors such as physical activity and nutrition intake are known to optimize the peak bone mass (PBM). Recently, intake of polyunsaturated fatty acids (PUFAs) has been reported to contribute to bone metabolism...
June 23, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28606219/dietary-calcium-intake-and-rate-of-bone-loss-in-men
#8
RANDOMIZED CONTROLLED TRIAL
Sarah M Bristow, Gregory D Gamble, Anne M Horne, Ian R Reid
A high Ca intake has been recommended for osteoporosis prevention; however, little research has examined the relationship between dietary Ca and bone health in men. We examined associations between dietary Ca intake, bone mineral density (BMD) and change in BMD at the total body, hip and spine over 2 years in a cohort of men (mean age 57 years, BMI 26 kg/m2) from a trial. Data from the total cohort (n 323) were used in the analysis of Ca intake and BMD at baseline, and data from the placebo group (n 99) were used in the longitudinal analysis of Ca intake and change in BMD...
May 2017: British Journal of Nutrition
https://www.readbyqxmd.com/read/28608571/effects-of-denosumab-and-teriparatide-transitions-on-bone-microarchitecture-and-estimated-strength-the-data-switch-hr-pqct-study
#9
Joy N Tsai, Kyle K Nishiyama, David Lin, Amy Yuan, Hang Lee, Mary L Bouxsein, Benjamin Z Leder
In postmenopausal osteoporosis, switching from teriparatide to denosumab results in continued bone mineral density (BMD) gains whereas switching from denosumab to teriparatide results in BMD loss. To assess the effects of these transitions on bone microarchitecture and strength, we performed high-resolution peripheral QCT (HR-pQCT) at the distal tibia and radius in postmenopausal osteoporotic women who received 24 months of teriparatide 20 μg daily followed by 24 months of denosumab 60 mg every 6 months, 24 months of denosumab followed by 24 months of teriparatide, or 24 months of both medications followed by 24 months of denosumab...
June 13, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28602783/patient-reported-reasons-for-nonadherence-to-recommended-osteoporosis-pharmacotherapy
#10
Sylvie F Hall, Stephanie W Edmonds, Yiyue Lou, Peter Cram, Douglas W Roblin, Kenneth G Saag, Nicole C Wright, Michael P Jones, Fredric D Wolinsky
OBJECTIVES: As many as one-half of patients recommended for osteoporosis pharmacotherapy do not take their medications. To identify intervention targets, we examined patient characteristics associated with nonadherence to recommended pharmacotherapy and their reasons for nonadherence. METHODS: Data come from the Patient Activation after DXA Result Notification (PAADRN) study, a randomized controlled trial of 7749 patients aged 50 years or older presenting for dual-energy X-ray absorptiometry (DXA) at 3 health centers in the United States...
July 2017: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/28529724/recent-advances-in-the-management-of-osteoporosis
#11
REVIEW
Seiji Fukumoto, Toshio Matsumoto
There has been substantial progress in the management of patients with osteoporosis and the prevention of osteoporotic fractures. Currently available strong anti-resorptive agents are bisphosphonates and an anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody, denosumab. Although bisphosphonates and denosumab both inhibit bone resorption and prevent vertebral and non-vertebral fractures, their mechanisms of action are different. Whereas bisphosphonates' effects on bone mineral density and fracture peak around 3 to 5 years and become plateaued, those of denosumab are maintained for up to 10 years...
2017: F1000Research
https://www.readbyqxmd.com/read/28449657/influence-of-subject-discontinuation-on-long-term-nonvertebral-fracture-rate-in-the-denosumab-freedom-extension-study
#12
Jonathan D Adachi, Henry G Bone, Nadia S Daizadeh, Paula Dakin, Socrates Papapoulos, Peyman Hadji, Chris Recknor, Michael A Bolognese, Andrea Wang, Celia J F Lin, Rachel B Wagman, Serge Ferrari
BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study. METHODS: To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not...
April 27, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28458516/profile-of-romosozumab-and-its-potential-in-the-management-of-osteoporosis
#13
REVIEW
Sian Yik Lim, Marcy B Bolster
Increased understanding of bone biology has led to the discovery of several unique signaling pathways that regulate bone formation and resorption. The Wnt signaling pathway plays a significant role in skeletal development, adult skeletal homeostasis, and bone remodeling. Sclerostin is an inhibitor of the Wnt signaling pathway. Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect. Therefore, in the presence of romosozumab, the Wnt signaling pathway is activated leading to bone formation and bone mineral density gain...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28432596/exploiting-the-wnt-signaling-pathway-for-clinical-purposes
#14
REVIEW
Mark L Johnson, Robert R Recker
PURPOSE OF REVIEW: The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001-2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting...
April 21, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28379394/serum-25-hydroxyvitamin-d-insufficiency-in-search-of-a-bone-disease
#15
Sonali Shah, Cherie Chiang, Ken Sikaris, Zhong Lu, Minh Bui, Roger Zebaze, Ego Seeman
Context: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present. Methods: Concentrations of 25(OH)D, calcium, phosphate, creatinine, and parathyroid hormone (PTH) were measured in 11,855 participants...
July 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28416991/can-denosumab-be-a-substitute-competitor-or-complement-to-bisphosphonates
#16
REVIEW
Su Young Kim, Hwoe Gyeong Ok, Christof Birkenmaier, Kyung Hoon Kim
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-osteoclasts or mature osteoclasts, bone resorption increases. On the contrary, when OPG binds to the RANK, bone resorption decreases. Denosumab (AMG 162), like OPG (a decoy receptor), binds to the RANKL, and reduces binding between the RANK and the RANKL resulting in inhibition of osteoclastogenesis and reduction of bone resorption...
April 2017: Korean Journal of Pain
https://www.readbyqxmd.com/read/28359721/western-osteoporosis-alliance-clinical-practice-series-evaluating-the-balance-of-benefits-and-risks-of-long-term-osteoporosis-therapies
#17
REVIEW
David A Hanley, Michael R McClung, K Shawn Davison, Larry Dian, Steve T Harris, Paul D Miller, E Michael Lewiecki, David L Kendler
Osteoporosis is a chronic disease that requires life-long strategies to reduce fracture risk. Few trials have investigated the balance of benefits and risk with long-term use of osteoporosis therapies, and fewer still have investigated the consequences of treatment discontinuation. The best available evidence suggests that up to 10 years of treatment with an oral bisphosphonate maintains the degree of fracture risk reduction observed in the 3-year registration trials. With denosumab, 10 years of therapy appears to provide fracture risk reduction similar to or better than that observed in the 3-year registration trial...
July 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28283938/seasonal-variation-in-internet-searches-for-vitamin-d
#18
Rebecca J Moon, Elizabeth M Curtis, Justin H Davies, Cyrus Cooper, Nicholas C Harvey
Internet search rates for "vitamin D" were explored using Google Trends. Search rates increased from 2004 until 2010 and thereafter displayed a seasonal pattern peaking in late winter. This knowledge could help guide the timing of public health interventions aimed at managing vitamin D deficiency. PURPOSE: The Internet is an important source of health information. Analysis of Internet search activity rates can provide information on disease epidemiology, health related behaviors and public interest...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28283537/increased-osteoclastogenesis-in-patients-with-vertebral-fractures-following-discontinuation-of-denosumab-treatment
#19
Athanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, Grigorios T Sakellariou, Fotini Papadopoulou, Spyridon Gerou, Socrates E Papapoulos
OBJECTIVE: To test the hypothesis that rebound of bone remodeling is responsible for clinical vertebral fractures reported in a few patients with osteoporosis after cessation of denosumab treatment. DESIGN: In this case-control study we compared clinical and biochemical characteristics of postmenopausal women with clinical vertebral fractures 8-16 months after the last injection of denosumab (Dmab/Fx+, n = 5) with those of treatment-naïve women with such fractures (Fx+, n = 5)...
June 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28240371/clinical-features-of-24-patients-with-rebound-associated-vertebral-fractures-after-denosumab-discontinuation-systematic-review-and-additional-cases
#20
Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, Berengere Aubry-Rozier, Stella Kaouri, Olivier Lamy
We aimed to study the clinical and imaging characteristics of patients sustaining vertebral fractures after denosumab discontinuation. For this purpose, we conducted a computerized advanced literature search that identified 13 published cases, and we additionally included another 11 new cases from our centers. Twenty-four postmenopausal women with vertebral fracture(s) after denosumab discontinuation, experiencing 112 fractures in total, were analyzed. The mean number of fractures per patient was 4.7. The most commonly affected vertebrae were T12 and L1...
June 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
label_collection
label_collection
4860
1
2
2017-03-02 03:49:41
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"